Compare Stocks

→ Biden’s $374B Giveaway Into This Sector (From DTI) (Ad)

Compare stocks and their fundamentals, performance, price, and technicals. Use this free stock comparison tool to evaluate companies based on their analyst ratings, book value, debt, dividend, MarketRank, news sentiment, price performance, profitability, and more. Enter up to ten stock symbols separated by a comma or space (ex. BAC, JPM, WFC, C, GS).

Comparative Price Performance Over Time

Compare Stocks - Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
OKYO OKYO Pharma	$1.47 +4.3%	$1.45	$0.92 ▼ $3.25	$42.25M	0.04	161,834 shs	7,176 shs
OPTI Optec International	$0.00	$0.00	$0.00 ▼ $0.00	$31K	N/A	42.40 million shs	49.65 million shs
TRX TRX Gold	$0.46 +2.2%	$0.38	$0.31 ▼ $0.60	$128.61M	0.65	349,012 shs	405,181 shs
VIRI Virios Therapeutics	$0.44 -2.2%	$0.41	$0.28 ▼ $2.42	$8.54M	1.88	363,441 shs	62,644 shs

7 Stocks to Own Before the 2024 Election

Looking to avoid the hassle of mudslinging, volatility, and uncertainty? You'd need to be out of the market, which isn’t viable. So where should investors put their money? Find out with this report.

Get This Free Report

Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
OKYO OKYO Pharma	+4.26%	+10.53%	-0.34%	-9.26%	+17.60%
OPTI Optec International	0.00%	-34.15%	0.00%	+145.45%	+671.43%
TRX TRX Gold	+3.27%	+0.46%	+23.12%	+27.38%	-14.05%
VIRI Virios Therapeutics	-1.49%	-5.68%	+25.23%	-45.34%	-35.47%

You’re invited: Biggest crypto event of 2024 (Ad)

During the event on Tuesday, April 23 at 10 am ET, I’ll be giving away the name and ticker symbol of crypto that could surge in price. I believe it will be the best performing crypto of 2024.

Just click here to sign up and be among the first to get it.

MarketRank™

Company	Overall Score	Analyst's Opinion	Short Interest Score	Dividend Strength	ESG Score	News and Social Media Sentiment	Company Ownership	Earnings & Valuation
OKYO OKYO Pharma	1.589 of 5 stars	3.5	3.0	0.0	0.0	0.6	1.7	0.6
OPTI Optec International	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
TRX TRX Gold	3.2369 of 5 stars	3.5	0.0	0.0	0.0	3.1	0.0	3.1
VIRI Virios Therapeutics	0.1133 of 5 stars	0.0	3.0	0.0	0.0	2.2	0.8	0.0

Analyst Ratings

Company	Consensus Rating Score	Consensus Rating	Consensus Price Target	% Upside from Current Price
OKYO OKYO Pharma	3.00	Buy	$7.00	377.72% Upside
OPTI Optec International	N/A	N/A	N/A	N/A
TRX TRX Gold	3.00	Buy	$1.58	241.57% Upside
VIRI Virios Therapeutics	N/A	N/A	N/A	N/A

Current Analyst Ratings

Latest VIRI, OPTI, OKYO, TRX, and HVO Analyst Ratings

Date	Company	Brokerage	Action	Rating	Price Target
4/16/2024	TRX TRX Gold	Alliance Global Partners Subscribe to MarketBeat All Access for the recommendation accuracy rating	Boost Price Target	Buy ➝ Buy	$1.50 ➝ $1.75
4/16/2024	TRX TRX Gold	HC Wainwright Subscribe to MarketBeat All Access for the recommendation accuracy rating	Boost Price Target	Buy ➝ Buy	$1.30 ➝ $1.40
3/22/2024	OKYO OKYO Pharma	HC Wainwright Subscribe to MarketBeat All Access for the recommendation accuracy rating	Boost Price Target	Buy ➝ Buy	$6.00 ➝ $7.00

(Data available from 4/19/2021 forward. View 10+ years of historical ratings with our analyst ratings screener.)

Sales & Book Value

Company	Annual Revenue	Price/Sales	Cashflow	Price/Cash	Book Value	Price/Book
OKYO OKYO Pharma	N/A	N/A	N/A	N/A	($0.08) per share	N/A
OPTI Optec International	N/A	N/A	N/A	N/A	N/A	N/A
TRX TRX Gold	$38.32M	3.36	$0.01 per share	36.04	$0.23 per share	2.00
VIRI Virios Therapeutics	N/A	N/A	N/A	N/A	$0.20 per share	N/A

Profitability & Earnings

Company	Net Income	EPS	Trailing P/E Ratio	Forward P/E Ratio	P/E Growth	Net Margins	Return on Equity (ROE)	Return on Assets (ROA)	Next Earnings Date
OKYO OKYO Pharma	-$13.27M	N/A	0.00	N/A	N/A	N/A	N/A	N/A	8/20/2024 (Estimated)
OPTI Optec International	N/A	N/A	0.00	∞	N/A	N/A	N/A	N/A	N/A
TRX TRX Gold	$2.25M	$0.01	46.16	6.59	N/A	0.70%	-1.66%	-1.18%	N/A
VIRI Virios Therapeutics	-$5.30M	-$0.28	N/A	N/A	N/A	N/A	-110.15%	-100.18%	5/9/2024 (Estimated)

Latest VIRI, OPTI, OKYO, TRX, and HVO Earnings

Date	Quarter	Company	Consensus Estimate	Reported EPS	Beat/Miss	Gap EPS	Revenue Estimate	Actual Revenue	Details
4/12/2024	Q2 2024	TRX TRX Gold	N/A	$0.01	+$0.01	N/A	$9.40 million	$7.98 million
2/29/2024	Q4 2023	VIRI Virios Therapeutics	-$0.09	-$0.06	+$0.03	-$0.06	N/A	N/A

Dividends

Company	Annual Payout	Dividend Yield	3-Year Dividend Growth	Payout Ratio	Years of Consecutive Growth
OKYO OKYO Pharma	N/A	N/A	N/A	N/A	N/A
OPTI Optec International	N/A	N/A	N/A	N/A	N/A
TRX TRX Gold	N/A	N/A	N/A	N/A	N/A
VIRI Virios Therapeutics	N/A	N/A	N/A	N/A	N/A

Debt

Company	Debt-to-Equity Ratio	Current Ratio	Quick Ratio
OKYO OKYO Pharma	N/A	N/A	N/A
OPTI Optec International	N/A	N/A	N/A
TRX TRX Gold	N/A	0.93	0.61
VIRI Virios Therapeutics	N/A	11.60	11.60

Ownership

Institutional Ownership

Company	Institutional Ownership
OKYO OKYO Pharma	2.97%
OPTI Optec International	N/A
TRX TRX Gold	1.06%
VIRI Virios Therapeutics	9.05%

Insider Ownership

Company	Insider Ownership
OKYO OKYO Pharma	40.46%
OPTI Optec International	50.34%
TRX TRX Gold	2.25%
VIRI Virios Therapeutics	11.70%

Miscellaneous

Company	Employees	Shares Outstanding	Free Float	Optionable
OKYO OKYO Pharma	8	28.83 million	17.17 million	Not Optionable
OPTI Optec International	1	11.65 million	N/A	Not Optionable
TRX TRX Gold	130	278.92 million	272.64 million	Optionable
VIRI Virios Therapeutics	4	19.26 million	17.01 million	Optionable

VIRI, OPTI, OKYO, TRX, and HVO Headlines

Source	Headline
	Virios Therapeutics, Inc. (VIRI) finance.yahoo.com - April 14 at 7:23 PM
	Virios Therapeutics, Inc. (NASDAQ:VIRI) Sees Large Growth in Short Interest americanbankingnews.com - April 13 at 3:46 AM
	Virios Therapeutics seeks global patent for antiviral combo investing.com - March 28 at 11:45 PM
	Virios Therapeutics Announces Publication of International Patent for IMC-2 Covering Antiviral Treatment of Long-COVID globenewswire.com - March 26 at 9:15 AM
	Virios Therapeutics announces salary cuts for employees and board investing.com - February 29 at 5:35 PM
	Virios Therapeutics Announces Fourth Quarter and Full Year 2023 Financial Results markets.businessinsider.com - February 29 at 12:35 PM
	Virios Therapeutics Announces Fourth Quarter and Full Year 2023 Financial Results globenewswire.com - February 29 at 9:15 AM
	Virios Therapeutics Issues Shareholder Letter Highlighting Corporate Progress and Key Upcoming Milestones markets.businessinsider.com - February 28 at 11:24 AM
	Virios Therapeutics Issues Shareholder Letter Highlighting Corporate Progress and Key Upcoming Milestones globenewswire.com - February 28 at 9:15 AM
	Virios Therapeutics Llc (VIRI) investing.com - February 27 at 7:37 AM
	Virios Therapeutics (VIRI) Price Target Increased by 14.29% to 4.08 msn.com - February 25 at 12:10 AM
	Virios Therapeutics Inc Ordinary Shares VIRI morningstar.com - February 9 at 12:13 AM
	VIRI: Moving IMC-2 into Phase 2 Program in Long COVID finance.yahoo.com - February 7 at 1:09 PM
	Fibromyalgia Treatment Market revenue to cross USD 536 Million by 2033, says Research Nester finance.yahoo.com - February 6 at 3:37 PM
	Virios Therapeutics Stock (NASDAQ:VIRI) Dividends: History, Yield and Dates benzinga.com - January 23 at 10:37 PM
	Virios Therapeutics to advance development of IMC-2 as treatment for symptoms associated with long-Covid pharmabiz.com - January 23 at 7:35 AM
	Virios Therapeutics Announces Plans to Advance Development of IMC-2 as Treatment for Symptoms Associated with Long-COVID finanznachrichten.de - January 22 at 3:19 PM
	Virios Therapeutics Announces Plans to Advance Development of IMC-2 as Treatment for Symptoms Associated with Long-COVID finance.yahoo.com - January 22 at 10:18 AM
	Virios Therapeutics, Inc. Reaches Alignment with FDA on Requirements for Advancing Development ... bakersfield.com - January 2 at 9:21 AM
	Virios Therapeutics Reports Receipt Of FDA's Feedback On Requirements For Advancing IMC-2 markets.businessinsider.com - January 2 at 9:21 AM
	Virios Therapeutics, Inc. Reaches Alignment with FDA on Requirements for Advancing Development Candidate IMC-2 as Treatment for Long-COVID finance.yahoo.com - January 2 at 9:21 AM
	Taking a Closer Look At Virios Therapeutics Inc (VIRI) Following Its Recent Trade knoxdaily.com - January 1 at 8:34 AM
	Virios Therapeutics Inc Ordinary Shares morningstar.com - December 7 at 10:47 PM
	Virios Therapeutics, Inc. (NASDAQ:VIRI) Q3 2023 Earnings Call Transcript finance.yahoo.com - November 14 at 1:38 PM

New MarketBeat Followers Over Time

Media Sentiment Over Time

Top Headlines

3 Stocks With Unusual Call Option Activity
March 26, 2024 1:10 PM
View 3 Stocks With Unusual Call Option Activity
Best Bear Market Funds: Top 3 Investment Options to Consider
March 27, 2024 10:58 AM
View Best Bear Market Funds: Top 3 Investment Options to Consider
Delta Airline’s Put Option Activity Isn’t Bad News
March 28, 2024 8:55 AM
View Delta Airline’s Put Option Activity Isn’t Bad News
How and When to Roll Your Options Positions?
March 27, 2024 9:32 AM
View How and When to Roll Your Options Positions?
Robinhood’s Credit Card Has Call Option Buyers Coming in Hot
April 3, 2024 8:45 AM
View Robinhood’s Credit Card Has Call Option Buyers Coming in Hot

All Headlines

Company Descriptions

OKYO Pharma

NASDAQ:OKYO

OKYO Pharma Limited, a clinical-stage biopharmaceutical company, engages in developing therapeutics for patients suffering from inflammatory eye diseases and ocular pain in the United Kingdom. Its lead preclinical product candidate is OK-101, which is in Phase II clinical trials for the treatment of dry eye disease. The company is also developing OK-201, a bovine adrenal medulla, lipidated-peptide preclinical analogue candidate for the treatment of neuropathic chronic pain. The company was incorporated in 2007 and is headquartered in London, the United Kingdom.

Optec International

OTCMKTS:OPTI

Optec International, Inc. engages in selling and marketing optimized fuel maximizer units in North America and internationally. It markets optimized fuel maximizer for passenger vehicles, intermediate/medium duty trucks, off-road equipment, generator systems, heavy duty diesel on-road vehicles, and transportation refrigeration units. The company was formerly known as Green Meadow Products, Inc. and changed its name to Optec International, Inc. in August 2017. Optec International, Inc. was founded in 2012 and is based in Carlsbad, California.

TRX Gold

NYSE:TRX

TRX Gold Corporation engages in the exploration, development, and production of mineral property interests in the United Republic of Tanzania. The company primarily explores for gold deposits. It holds interests in the Buckreef gold project that comprises a single Special Mining License covering an area of 16.04 square kilometers and 12 Prospecting Licenses covering 98.19 square kilometers located in north-central Tanzania. The company was formerly known as Tanzanian Gold Corporation and changed its name to TRX Gold Corporation in May 2022. TRX Gold Corporation was incorporated in 1990 and is based in Oakville, Canada.

Virios Therapeutics

NASDAQ:VIRI

Virios Therapeutics, Inc., a development-stage biotechnology company, focuses on developing novel antiviral therapies to treat diseases associated with a viral triggered abnormal immune response. The company's lead development candidate is the IMC-1, a fixed dose combination of famciclovir and celecoxib to treat fibromyalgia. It also develops IMC-2, a combination of valacyclovir and celecoxib for the treatment of managing the fatigue, sleep, attention, pain, autonomic function, and anxiety associated with long COVID. The company was formerly known as Innovative Med Concepts, LLC and changed its name to Virios Therapeutics, Inc. in July 2020. Virios Therapeutics, Inc. was founded in 2012 and is headquartered in Alpharetta, Georgia.

Get 30 Days of MarketBeat All Access Free

Best-in-Class Portfolio Monitoring
View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio.
Stock Ideas and Recommendations
Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report.
Advanced Stock Screeners and Research Tools
Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis.

Start Your 30-Day Free Trial